[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 1B, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosentuzumab to Participants with Systemic Lupus Erythemastosus. GA43191

What is the purpose of the study? (in Layman's terms, please describe the study)

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).

Upstate Institutional Review Board (IRB) Number:

1821375

Study/Protocol ID:

GA43191

Study Phase:

Phase 1

Patient Age Group:

Adults

Principal Investigator:

Andras Perl, MD, PhD

What is involved if I participate?

  • How long is the study?
    N/A
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    N/A

Where will the study take place?

The Hill Medical Center - 1000 E Genesee St, Syracuse, NY 13210

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT05155345

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Bryan Blaker
Phone: 315-464-6481
Email: [email protected]

Return to Previous Page || Search Again

Top